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Background. Antilipoprotein lipase (anti-LPL) antibodies were described in rheumatic diseases. In systemic lupus erythematosus
they were highly associated with inﬂammatory markers and dyslipidemia, and may ultimately contribute to vascular damage. The
relevance of this association in Takayasu’s arteritis, which is characterized by major inﬂammatory process aﬀecting vessels, has not
been determined. Objectives. To analyze the presence of anti-LPL antibodies in patients with Takayasu’s arteritis and its association
with inﬂammatory markers and lipoprotein risk levels. Methods. Thirty sera from patients with Takayasu’s arteritis, according to
ACR criteria, were consecutively included. IgG anti-LPL was detected by a standard ELISA. Lipoprotein risk levels were evaluated
according to NCEP/ATPIII. Inﬂammatory markers included ESR and CRP values. Results. Takayasu’s arteritis patients had a mean
age of 34 years old and all were females. Half of the patients presented high ESR and 60% elevated CRP. Lipoprotein NCEP risk
levelswereobservedinapproximatelyhalfofthepatients:53%fortotalcholesterol,43%fortriglycerides,16%forHDL-cand47%
for LDL-c. In spite of the high frequency of dyslipidemia and inﬂammatory markers in these patients no anti-LPL were detected.
Conclusions. The lack of anti-LPL antibodies in Takayasu’s disease implies distinct mechanisms underlying dyslipidemia compared
to systemic lupus erythematosus.
Copyright © 2009 Joz´ elio Freire de Carvalho et al. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
1.Introduction
Antilipoprotein lipase (anti-LPL) antibodies have been
recently described in rheumatic diseases, mainly in systemic
lupus erythematosus (SLE) and systemic sclerosis (SSc) but
also in polymyositis and rheumatoid arthritis [1]. Lipopro-
tein lipase is a key enzyme in triglycerides metabolism
and the presence of these autoantibodies might explain
dyslipoproteinemias in these diseases. In fact, anti-LPL
antibodies were identiﬁed in approximately 40% of lupus
patients [1, 2] and were associated with high triglycerides
(TGs)levels[2].Inaddition,theinﬂuenceoftheseantibodies
on triglyceride metabolism was also conﬁrmed in SSc since
LPL activity was inhibited by anti-LPL in SSc sera of patients
with elevated triglyceride levels [3].
The presence of cellular inﬁltrates in vessels wall, as
well as, the overexpression of cell-adhesion molecules on
the endothelial cell membrane is a hallmark of chronic
inﬂammatory disorders such as Takayasu’s arteritis [4]. Since
lipoprotein lipase is localized on endothelial surface of all
vascular system carrying out triglycerides hydrolysis [5], it is
therefore reasonable to speculate that the lipoprotein lipase
may be involved in the inﬂammatory vascular process of
Takayasu’s arteritis [6, 7].
The present study was undertaken to determine the
presence of antilipoprotein lipase antibodies and its possible
link with dyslipoproteinemia and inﬂammatory markers in
patients with Takayasu’s arteritis.
2.MaterialandMethods
2.1. Patients. A total of thirty premenopausal female
Takayasu’s arteritis (TAs) patients that satisﬁed the proposed
criteria of American College of Rheumatology for [8]w e r e
consecutively enrolled, from the Outpatient Clinics at the
Rheumatology Division of S˜ ao Paulo University Medical
School. At entry, all patients were clinically evaluated, their2 Clinical and Developmental Immunology
medical records were extensively reviewed and a blood
sample was collected.
Rigorous exclusion criteria of conditions that interfere
in the lipid proﬁle, such as diabetes mellitus, pregnancy,
menopause,liverorthyroiddisease,ingestionoflipid-raising
drugsoruseofstatins,wereapplied.Thisstudywasapproved
by the Local Ethical Committee.
2.2. Laboratory Evaluation. Serum samples were obtained
from all patients after a 12-hour overnight fast after
inclusion. Immunological and biochemical analysis were
performed in the same serum samples.
2.3. Assay for Antibody to Lipoprotein Lipase (LPL) Detec-
tion. Anti-LPL reactivity of IgG isotype was measured by
Enzyme-linked immunosorbent assay (ELISA), as previously
described [2]. Brieﬂy, wells of Costar polystyrene plates
were coated overnight with commercially available LPL from
bovine milk (5µg/mL) (Sigma Chem. Co., St Louis, Mo,
USA). Test was performed with serum samples 1/100 diluted
in Tris buﬀered-saline containing adult bovine serum. Anti-
LPL IgG isotype antibodies were determined with alkaline-
phosphatase conjugated goat antihuman IgG (Sigma Chem.
Co., St Louis, Mo, USA). The reaction was developed with p-
nitrophenyl phosphate and optical density (OD) read at 405
nmwithaLabsystemsMultiskanMS(Helsinki,Finland).IgG
anti-LPLpositivitywasdeﬁnedforserumsamplesODvalues
≥ 3SD above the mean OD of 20 healthy control serum
samples included in each assay.
2.4. Lipid Proﬁles. Total cholesterol (TC) and triglycerides
(TG) were measured enzymatically (Boehringer Mannheim,
Argentina and Merck, Germany, resp.) on an RA 1000
analyser (Technicon Instruments Corp) [9, 10]. High-
density lipoprotein cholesterol (HDL) was obtained after
precipitation of very low-density lipoprotein cholesterol
(VLDL) and low-density lipoprotein cholesterol (LDL) by
phosphotungstic acid and magnesium chloride [11]. VLDL
and LDL were estimated since all samples had triglycerides
less than 400mg/dL [12]. VLDL levels were calculated from
the division of serum triglyceride by 5 (TG/5) [12]a n dL D L
levels were estimated using the equation: LDL = TC −
(HDL + TG/5) [12]. Risk lipoprotein levels were determined
according to National Cholesterol Education Program-Adult
Treatment Panel III (NCEP/ATPIII) [13].
2.5. Inﬂammatory Markers. C-reactive protein (CRP) serum
levels were systematically determined in all patients by
nephelometry. Erythrocyte sedimentation rate (ESR) was
measured by modiﬁed Westergren method. These parame-
ters were considered to be altered when CRP > 5µg/mL and
ESR > 25mm/ﬁrst hour.
2.6. Statistical Analysis. Results are presented as the mean ±
SD and percentage. Correlations among inﬂammatory
markers and lipoprotein risk levels were calculated using
Spearman’srankcorrelationtest.P-valueslessthan0.05were
considered signiﬁcant.
Table 1: Demographic, clinical features and prednisone use of
patients with Takayasu’s arteritis. Values are expressed in mean ±
SD or percentage (%).
Takayasu’s arteritis
(n = 30)
Age (years) 33.8 ±8.1
White race, n (%) 21 (70)
Body mass index (kg/m2) 25.5 ±5.5
Disease duration (years) 6.7 ±6.9
Prednisone use, n (%) 17 (56.6)
Current prednisone dose (mg/day) 9.7 ±13.7
Systemic arterial hypertension, n (%) 24 (80)
Table 2: Risk levels of Takayasu’s arteritis patients according to
NCEP/ATPIII. HDL-c = high-density lipoprotein cholesterol; LDL-
c = low-density lipoprotein cholesterol.
Takayasu’s arteritis
(n = 30)
Total cholesterol > 200mg/dL, n (%) 16 (53.3)
HDL-c < 40mg/dL, n (%) 5 (16.6)
LDL-c > 130mg/dL, n (%) 14 (46.6)
Triglycerides > 150mg/dL, n (%) 13 (43.3)
Any lipoprotein NCEP/ATPIII risk level, n (%) 20 (66.6)
3. Results
3.1. Demographic Features. Takayasu’s arteritis female
patients (n = 30) had a mean age of 33.8±8.1 years and 70%
were white race. All patients had body mass index below
30kg/m2 and the mean disease duration was 6.7 ± 6.9y e a r s .
More than half (57%) of patients studied were in use of
prednisone but low daily doses were observed in TA patients
(9.7 ± 13.7mg/d). Systemic arterial hypertension (Blood
pressure ≥ 140 × 90mmHg, or antihypertensive use) was
observed in eighty percent of TA patients (Table 1).
3.2. Lipoprotein Proﬁle. In these premenopausal TA patients,
the mean levels of total cholesterol were 205.7 ± 35.5mg/dL,
HDL-c 57.1 ± 18.7mg/dL, and LDL-c 122.8 ± 31.2mg/dL,
and triglyceride was 126.7 ± 61.3mg/dL.
Moderate/high lipoprotein risk levels according to
NCEP/ATPIII were observed in these subjects due to high
total cholesterol in 53.3% (n = 16), low HDL-c in 16.6%
(n = 5), high LDL-c in 46.6% (n = 14), and high triglyceride
levels in 43.3% (n = 13). In addition, approximately half
of the TA patients presented any lipoprotein risk levels
(Table 2).
3.3. Antilipoprotein Lipase Antibodies. No antilipoprotein
lipase antibodies measured by ELISA was detected in TA
patients.
3.4. Inﬂammatory Parameters. TA patients exhibited a more
pronounced inﬂammatory alterations and had a mean
ESR of 25.8 ± 17.6mm/1st hour and a mean CRP ofClinical and Developmental Immunology 3
Table 3: Inﬂammatory markers in patients Takayasu’s arteritis.
Values are expressed in mean ± SD or percentage (%).
Takayasu’s arteritis
(n = 30)
C-reactive protein (mcg/mL) 11 ±12.4
Erythrocyte sedimentation rate (mm/1st h) 25.8 ±17.6
C-reactive protein >5mcg/mL,n (%) 18 (60)
Erythrocyte sedimentation rate >25mm/1st h,
n (%) 15 (50)
11 ± 12.4mcg/mL. Moreover, increased levels of CRP were
observed in 60% of TA group and 50% presented elevated
ESR (Table 3).
A correlation analysis performed between inﬂammatory
parameters and lipoproteins showed a signiﬁcant negative
correlation between CRP and HDL-c (r =− 0.40; P =
.028) but not with triglycerides (r = 0.16; P = .39), total
cholesterol (r =− 0.18; P = .34), and LDL-c (r =− 0.007;
P = .96).
4. Discussion
Results from the current study showed that patients with
Takayasu’s arteritis do not present antibodies to lipoprotein
lipase, although about seventy percent of them had at least
one lipid risk levels for cardiovascular disease.
Importantly, we have selected only premenopausal
female since the lipid proﬁle is compromised due to the
estrogen deﬁciency [14–16] and also gender is an important
parameter that accounts for dyslipidemia studies [14, 16].
Importantly,allourpatientshadbody massindex lowerthan
30kg/m2, since obesity is a well known factor that modiﬁes
the lipid proﬁle [14].
Moreover, the rigorous exclusion criteria used to select
Takayasu’s patients without other conditions that could
interfere with lipid metabolism, such as, diabetes, thyroid
disease, renal and hepatic involvements provided an oppor-
tunity to study the role of anti-LPL exclusively on Takayasu’s
disease without the inﬂuence of external factors [16–19].
Analysis of lipid proﬁle revealed that in the patients with
Takayasu’s disease present lipid risk levels for cardiovascular
disease due to high total cholesterol, high LDL-c and high
triglycerides and low-HDL-c. These ﬁndings were similar to
those found in chronic inﬂammatory disorders associated
with atherosclerosis [20–22] such as systemic lupus erythe-
matosus (SLE).
Anti-LPL autoantibodies have been implicated in the
inﬂammatory mechanisms of atherosclerosis in SLE and
other inﬂammatory autoimmune disease [1, 3]w i t ha n
evident vascular damage [23]. These antibodies were closely
associated to the elevated levels of triglycerides in SLE and
SSc and a putative functional role of anti-LPL in these
diseases came from the observation that IgG fraction from
SSc patient anti-LPL positive and with elevated serum
triglyceride levels was able to signiﬁcantly inhibit in vitro the
enzyme activity [3]. Also, in our previous study that evalu-
ated 66 SLE patients, with exclusion causes of dyslipidemia,
we found positive anti-LPL in 37.8% of them. Moreover, this
study showed a strong correlation between antilipoprotein
lipase antibodies and CRP [2].
Although a high frequency of elevated inﬂammatory
markers was observed in our TA patients, as well as a
negative correlation between CRP with HDL-c, similar to
found in lupus [2], the absence of a reactivity to lipoprotein
lipase suggests that anti-LPL antibodies are not implicated
in the ongoing active complex inﬂammatory process causing
vascular damage in TA.
In this aspect, it is reasonable to speculate that inﬂam-
matory and dyslipidemia processes occurring in TA and
in systemic connective tissue diseases (SLE and SSc) may
reﬂect diverse pathogenic mechanisms. In fact, systemic
vasculitis are well known pauci-immune pathophysiological
conditions. On the other hand, Shoenfeld et al. have
previously demonstrated that antiendothelial cell antibodies
may directly stimulate endothelial cells in TA through
elevation of adhesion molecule expression associated with
NF-kappaB activation and adhesion of monocytes, and may
therefore play a pathogenic role in the development of the
vasculopathy in this systemic disorder [24–26].
The present data are conclusive in showing that anti-
LPL antibodies are not implicated in the pathophysiology
of inﬂammatory atherosclerosis processes of Takayasu’s
arteritis.
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